Conversion from dopamine agonists to cabergoline: An open-label trial in 128 patients with advanced Parkinson disease

Clinical Neuropharmacology

Volumn 31, Issue 1, 2008, Pages 19-24

  Linazasoro, Gurutz ^a,b  

^a Centro de Investigación de Parkinson Policlínica Guipúzcoa   (Spain)

^b Centro de Investigacion Parkinson   (Spain)

Author keywords

Cabergoline; Dopamine agonists; Motor complications; Parkinson disease

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSKINESIA; DYSPNEA; FACE EDEMA; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPTIMAL DRUG DOSE; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RESPIRATORY ARREST; VASCULAR DISEASE;

AGED; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; INDOLES; MALE; PARKINSON DISEASE; PERGOLIDE;

EID: 40049083835     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/wnf.0b013e318067bcc4     Document Type: Article

References (31)

1. Uitti RJ, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinson's disease. Drugs 1996;5:369-388.
2. Wiseman LR, Fitton A. Cabergoline. A review of its efficacy in the treatment of Parkinson's disease. CNS Drugs 1999;12:485-497.
3. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double blind levodopa controlled trial. Drugs 1998;55(suppl 1):23-40.
4. Ahlskog JE, Wright KF, Muenter MD, et al. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996;19:202-212.
5. Hutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebo-controlled trial of cagbergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996;46:1062-1065.
6. Lera G, Vaamonde J, Rodr?́guez M, et al. Cabergoline in Parkinson's disease: long-term follow-up. Neurology 1993;43:2587-2590.
7. Goetz CG, Tanner CM, Glantz RH. Chronic agonist therapy for Parkinson's disease: a five-year study of bromocriptine and pergolide. Neurology 1985;35:749-751.
8. Goetz CG, Shannon KM, Tanner CM. Agonist substitution in advanced Parkinson's disease. Neurology 1989;39:1121-1122.
9. Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson's disease. Is rapid titration preferable to slow? Neurology 1999;52:1227-1229.
10. Hanna PA, Ratkos L, Ondo WG, et al. Switching from pergolide to pramipexole in patients with Parkinson's disease. J Neural Transm 2001;108:63-70.
11. Hauser R, Reider C, Stacey M, et al. Acute versus gradual pramipexole to ropinirole switch. Mov Disord 2000;15(suppl 3):133.
12. Canesi M, Antonini A, Mariani CB, et al. An overnight switch to ropinirole therapy in patients with Parkinson's disease. J Neural Transm 1999;106:925-929.
13. Giménez Roldán S, Esteban EM, Mateo D. Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios. Clin Neuropharmacol 2001;24:346-351.
14. Jost WH. Equivalent doses of ropinirole and bromocriptine [Letter]. Eur J Neurol 1999;6:618.
15. Linazasoro G on behalf of the Spanish Dopamine Agonists Study Group. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease. J Neurol 2004;251:335-340.
16. Shulman LM, Minagar A, Weiner WJ. The tolerability and efficacy of pramipexole in patients with idiopathic Parkinson's disease previously on bromocriptine, pergolide or cabergoline. Neurology 1998;50:A279.
17. Shiraishi M, Kamo T, Hotta M, et al. Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson's disease. J Neural Transm 2004;111:725-732.
18. Gibb WR, Lees AJ. The relevance of Lewy body to the pathogenesis of Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
19. Stocchi F, Vacca L, Ruggieri S, et al. Intermittent vs continuous levodopa administration in patients with advanced Parkinson's disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62: 905-911.
20. Linazasoro G. New ideas on the pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: age, genes and neural plasticity. Trends Pharmacol Sci 2005;26:391-397.
21. Grosset K, Needleman F, Macphee G, et al. Switching from ergot to non-ergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Mov Disord 2004;19:1370-1372.
22. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363:1179-1183.
23. Van Camp G, Flamez A, Cosyns B, et al. Herat valvular disease in patients with Parkinson's disease treated with high dose pergolide. Neurology 2003;61:859-861.
24. Baseman D, O'Suilleahbain PE, Reynold SC, et al. Pergolide use in Parkinson's disease is associated with cardiac valve regurgitation. Neurology 2004;63:301-304.
25. Pritchett AM, Morrison JF, Edwards WD, et al. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002;77:1280-1286.
26. Horvath J, Fross RD, Keiner G, et al. Severe multivalvular heart disease: a new complication of the ergot dopamine agonists. Mov Disord 2004;19:656-662.
27. Pinero A, Marcos-Alberca P, Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 2005;353:1976-1977.
28. Peralta C, Wolf E, Alber H, et al. Valvular heart disease in Parkinson's disease vs. controls: an echocardiographic study. Mov Disord 2006;21:1109-1113.
29. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 2006;67:1225-1229.
30. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46.
31. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38.